Evaluating Strategies to Assess Safety Profile of ADCs Under Development - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Evaluating Strategies to Assess Safety Profile of ADCs Under Development

10:00 am - Monday 12th October 2026

Understanding strategies to accelerate development cycle for ADCs
Evaluating in vitro assays to employ for early safety profiling leading up to in vivo studies

Speakers:

Malini Iyer

Malini Iyer

Associate Director, Oncology Safety Sciences

AstraZeneca